PA
XENE icon

Parallel Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Parallel Advisors’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.87K Sell
31
-121
-80% -$6.72K ﹤0.01% 3534
2026
Q1 		$8.84K Buy
152
+5
+3% +$230 ﹤0.01% 2806
2025
Q4 		$6.59K Hold
147
– – ﹤0.01% 2758
2025
Q3 		$5.9K Buy
147
+12
+9% +$423 ﹤0.01% 2719
2025
Q2 		$4.23K Sell
135
-553
-80% -$18K ﹤0.01% 2801
2025
Q1 		$23.1K Buy
688
+222
+48% +$8.43K ﹤0.01% 2066
2024
Q4 		$18.3K Buy
466
+85
+22% +$3.51K ﹤0.01% 2185
2024
Q3 		$15K Sell
381
-776
-67% -$31.3K ﹤0.01% 2236
2024
Q2 		$45.1K Hold
1,157
– – ﹤0.01% 1583
2024
Q1 		$49.8K Buy
1,157
+32
+3% +$1.47K ﹤0.01% 1500
2023
Q4 		$51.8K Buy
1,125
+381
+51% +$13.5K ﹤0.01% 1416
2023
Q3 		$25.4K Sell
744
-32
-4% -$1.2K ﹤0.01% 1715
2023
Q2 		$29.9K Buy
+776
New +$30.8K ﹤0.01% 1657

Other funds holding XENE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Parallel Advisors's XENE Position: Q2 2026 in Review

Parallel Advisors reduced its Xenon Pharmaceuticals (XENE) stake by 80% in Q2 2026, selling an estimated $6.72K and leaving 31 shares worth $1.87K. The position accounts for ﹤0.01% of the portfolio, ranked #3534.

Parallel Advisors first reported a position in XENE in Q2 2023 and has held it in 13 quarters since. The position peaked at $51.8K in Q4 2023. 96 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Parallel Advisors held 31 shares of Xenon Pharmaceuticals worth $1.87K as of Q2 2026.
  • Parallel Advisors sold 121 Xenon Pharmaceuticals shares in Q2 2026, an estimated $6.72K.
  • Xenon Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3534 holding.
  • Parallel Advisors first reported a position in Xenon Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • Parallel Advisors's Xenon Pharmaceuticals position peaked at $51.8K in Q4 2023.
  • 96 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.